Adherence to lipid-lowering therapy after cardiac rehabilitatio

• Conditions: Coronary Heart Disease; I20-I25; Ischaemic heart diseases

• Registration Number: DRKS00010514
• Lead Sponsor: Paracelsus-Harz-KlinikKardiologie, Pneumologie, Diabetes

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-05-13
• Study Completion: 2019-01-31
• Results First Posted: 2021-08-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1100

Inclusion Criteria

Age = 18 years
- Coronary Heard Disease
- lipid-lowering therapy
- inpatient hospital stay in one of the recruiting sites

Exclusion Criteria

- Lack of informed consent
- Diseases or disorders that may prevent a participation to this study according to the investigators judgement (dementia, psychotic disorders)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adherence to the recommended medication plan at discharge derived from the question, whether treatment plan was changed within 12 months since leaving the clinic (yes or no).

Secondary Outcome Measures

Name	Time	Method
1. Reason for the changes to the drug plan determined by the question whether the change(s) were made by the physician or by the patient.<br><br>2. Reason for the changes to the drug plan determined by the question whether the change(s) to the drug plan was induced by an intolerance to the drug pruduct.<br><br>3. Reaching of the treatment goal of lipid -lowering therapy during the rehabilitation stay, as measured by the LDL Cholesterien value (< 1.8 mmol/l = 70 mg/dl)<br>